AU2001283958A1 - Peptides presented by cells - Google Patents

Peptides presented by cells

Info

Publication number
AU2001283958A1
AU2001283958A1 AU2001283958A AU8395801A AU2001283958A1 AU 2001283958 A1 AU2001283958 A1 AU 2001283958A1 AU 2001283958 A AU2001283958 A AU 2001283958A AU 8395801 A AU8395801 A AU 8395801A AU 2001283958 A1 AU2001283958 A1 AU 2001283958A1
Authority
AU
Australia
Prior art keywords
peptides
cells
protein
polypeptide
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001283958A
Other languages
English (en)
Inventor
Francis J Carr
Graham Carter
Koen Hellendoorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Biovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovation Ltd filed Critical Biovation Ltd
Publication of AU2001283958A1 publication Critical patent/AU2001283958A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001283958A 2000-08-03 2001-07-26 Peptides presented by cells Abandoned AU2001283958A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018901.9 2000-08-03
GBGB0018901.9A GB0018901D0 (en) 2000-08-03 2000-08-03 Peptides presented by cells
PCT/EP2001/008625 WO2002012899A2 (fr) 2000-08-03 2001-07-26 Peptides presents par cellules

Publications (1)

Publication Number Publication Date
AU2001283958A1 true AU2001283958A1 (en) 2002-02-18

Family

ID=9896790

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001283958A Abandoned AU2001283958A1 (en) 2000-08-03 2001-07-26 Peptides presented by cells

Country Status (20)

Country Link
US (1) US20030171290A1 (fr)
EP (1) EP1305343B1 (fr)
JP (1) JP2004506202A (fr)
KR (1) KR20030037272A (fr)
CN (1) CN1511164A (fr)
AT (1) ATE306498T1 (fr)
AU (1) AU2001283958A1 (fr)
BR (1) BR0112925A (fr)
CA (1) CA2417767A1 (fr)
CZ (1) CZ2003464A3 (fr)
DE (1) DE60114018T2 (fr)
GB (1) GB0018901D0 (fr)
HU (1) HUP0301581A2 (fr)
MX (1) MXPA03000901A (fr)
NO (1) NO20030495D0 (fr)
PL (1) PL358874A1 (fr)
RU (1) RU2003105806A (fr)
SK (1) SK1982003A3 (fr)
WO (1) WO2002012899A2 (fr)
ZA (1) ZA200301637B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002023202A2 (fr) * 2000-09-18 2002-03-21 Genzyme Corporation Procede pour identifier des cibles d'anticorps therapeutiques associees a une reaction therapeutique
WO2009003492A1 (fr) 2007-07-03 2009-01-08 Dako Denmark A/S Procédés améliorés pour produire, marquer et utiliser des multimères du cmh
ATE386937T1 (de) * 2001-06-19 2008-03-15 Suntory Ltd Verfahren zur analyse eines in der zelle auftretenden proteins oder einer mit dem protein wechselwirkenden substanz
EP2481422A3 (fr) * 2003-09-03 2013-04-03 Dendritherapeutics, Inc. Vaccins multiplexes
AU2004283850C1 (en) 2003-10-16 2011-11-03 Amgen Research (Munich) Gmbh Multispecific deimmunized CD3-binders
US20090061478A1 (en) * 2006-01-30 2009-03-05 Lene Have Poulsen High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
EP2361930A3 (fr) 2007-03-26 2011-10-26 Dako Denmark A/S Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (fr) * 2008-07-23 2010-01-28 Dako Denmark A/S Analyse et réparation combinatoires
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
CA2778552A1 (fr) 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Traitement d'un cancer caracterise par la mutation des genes kras ou braf
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
WO2014184744A1 (fr) * 2013-05-13 2014-11-20 Cellectis Procédés de production, par génie génétique, d'un lymphocyte t hautement actif à vocation immunothérapeutique
US20170199961A1 (en) * 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
IL259023B (en) * 2016-09-30 2022-09-01 Cellex Life Sciences Incorporated Preparations containing protein-charged exosomes, methods for their production and uses thereof
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (fr) 2017-11-22 2021-10-27 Gritstone bio, Inc. Réduction de la présentation d'épitope de jonction pour des néo-antigènes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (fr) * 1997-05-21 1998-11-26 Biovation Limited Procede de production de proteines non immunogenes
JP2002534959A (ja) * 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
US6468537B1 (en) * 1999-04-28 2002-10-22 The Board Of Trustees Of Northwestern University Localization of major peptide autoepitopes for nucleosome specific T cells of systemic lupus erythematosus

Also Published As

Publication number Publication date
ATE306498T1 (de) 2005-10-15
KR20030037272A (ko) 2003-05-12
JP2004506202A (ja) 2004-02-26
CZ2003464A3 (cs) 2003-06-18
SK1982003A3 (en) 2003-08-05
GB0018901D0 (en) 2000-09-20
RU2003105806A (ru) 2004-07-20
EP1305343B1 (fr) 2005-10-12
MXPA03000901A (es) 2003-06-24
WO2002012899A3 (fr) 2002-11-07
CA2417767A1 (fr) 2002-02-14
CN1511164A (zh) 2004-07-07
US20030171290A1 (en) 2003-09-11
BR0112925A (pt) 2003-08-26
DE60114018D1 (de) 2006-02-23
WO2002012899A2 (fr) 2002-02-14
EP1305343A2 (fr) 2003-05-02
NO20030495L (no) 2003-01-31
NO20030495D0 (no) 2003-01-31
PL358874A1 (en) 2004-08-23
ZA200301637B (en) 2004-02-03
DE60114018T2 (de) 2006-06-29
HUP0301581A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
EP1305343B1 (fr) Peptides presents par cellules
US6391649B1 (en) Method for the comparative quantitative analysis of proteins and other biological material by isotopic labeling and mass spectroscopy
Wahlström et al. Identification of HLA-DR–bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis
JP5588584B2 (ja) 修飾ペプチドの定量化方法
EP3729958B1 (fr) Identification et surveillance d'immunoglobulines monoclonales par la masse moléculaire
US8568993B2 (en) Detection of glycopeptides and glycoproteins for medical diagnostics
Yan et al. Index-ion triggered MS2 ion quantification: a novel proteomics approach for reproducible detection and quantification of targeted proteins in complex mixtures
JP2010515020A (ja) 抗体定量法
Seppälä et al. Absolute quantification of allergens from complex mixtures: a new sensitive tool for standardization of allergen extracts for specific immunotherapy
EP1876448A1 (fr) Méthodes et réactifs analytiques pour identifier des médicaments à l'aide de marqueurs biologiques sensibles aux thiazolidinediones
EP3333571B1 (fr) Procédé de quantification parallèle de variantes d'épissage du facteur de croissance endothélial vasculaire (vegf-a)
Strollo et al. Autoantibody and T cell responses to oxidative post-translationally modified insulin neoantigenic peptides in type 1 diabetes
Schmidt et al. Immunoaffinity Targeted Mass Spectrometry Analysis of Human Plasma Samples Reveals an Imbalance of Active and Inactive CXCL10 in Primary Sjögren’s Syndrome Disease Patients
US20210285965A1 (en) Proteomic screening for diseases
Klug et al. Characterization of MHC ligands for peptide based tumor vaccination
CN111007161B (zh) 一种预测甲氨蝶呤药效的肽段组合物及其定量检测方法与检测试剂盒
Demine et al. Biochemical determination of natural tumor-associated T-cell epitopes
Lester Investigation of cellular responses to specific protein haptenation by low molecular weight chemical sensitisers
Safaei et al. Protein and Post Translational Modification in Asthma
Gurwitz Unravelling the molecular mechanisms of HIV associated neurocognitive disorders through mass spectrometry-based proteomics
Heyder et al. Approach for identifying HLA-DR bound peptides from scarce clinical samples
Lee Protein Set for Normalization of Quantitative Mass Spectrometry Data
Hodas Elucidating the hippocampal dopaminergic subproteome with novel bioorthogonal techniques
Purcell et al. 9 Mass Spectrometric Applications in Immunoproteomics
Arjunan Mapping of coronary endothelial cell membrane proteome and comparative proteomic analysis of regulatory T cells in CD73 knockout mice

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application